THE HEALTH ECONOMICS BLOG - Trends, Politics, Opinions etc. in biotech & pharma industry

Health Economics and HTA and its role in pricing and reimbursement, pipeline and in-lisencing evaluations as well as portfolio and company valuations in the biotech and pharmaceutical sector is ever increasing. While I was searching the web for various news on the topic, I actually couldn't find a blog that offers a platform of exchange among professionals in this field around the various topics - so there we go now and I hope you enjoy the information... Cheers Ulf

about the author

Ulf Staginnus is a health economist with more than 10 years of extensive international experience in health economics, pricing and reimbursement strategies as well as competitive intelligence and health technology valuations within the biotechnology and pharmaceutical industry (Novartis Oncology, Bristol-Myers Squibb, Pfizer Inc., Baxter Inc., GSK Biologicals). During the course of his career he also founded and run his own consultancy serving biotech and pharma clients in supporting product pricing, valuations and market access strategies. Ulf is Co-Editor of the Spanish Journal of Health Economics. He has been profiled in Marquis Who´s Who in America, Healthcare & Emerging Leaders.

THE HEALTH ECONOMICS BLOG - Trends, Politics, Opinions etc. in biotech & pharma industry

3.31.2008

Pharma Competitive Intelligence Conference

0 comments:

Blog Archive

Search the blog

Subscribe to my blog via email

about the author

Biotech Investing, Funds, Venture capital

Upcomming events

Economics

links related to health economics, biotechnology and competitive intelligence

Other industry news

HTA agencies